September 17th, 2026GLP-1 Receptor Agonists Cut Ascites, Mortality in MASHUltimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.Read more
September 17th, 2026Employment Masks Work Burden of Narcolepsy and HypersomniaA systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.Read more
September 17th, 2026Bridging IPF and Lung Cancer Care: Laura Fabbri, MDLaura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.Read more
September 17th, 2026FDA Expands Finerenone Approval to CKD Associated With Type 1 DiabetesFinerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.Read more
September 17th, 2026Targeting ROR1 May Offer a Way Around Resistance in MCLKarolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.Read more
September 16th, 2026Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 MutationsASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.Read more
September 16th, 2026Tafasitamab Results in Real-World Study on Par With Those in L-MINDReal-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.Read more
September 14th, 2026Beyond Eosinophils: COPD Biomarkers and Overtreatment RiskFrancesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.Read more